Abstract: SA-PO0838
Glomerular Disease Outcomes in Asian Americans in CureGN/NEPTUNE
Session Information
- Glomerular Diseases: Management, Evolving Strategies, and Practice-Changing Advances
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Karan, Meghana, Cohen Children's Medical Center, New York, New York, United States
- Basalely, Abby Miriam, Cohen Children's Medical Center, New York, New York, United States
- Castellanos, Laura J., Cohen Children's Medical Center, New York, New York, United States
- Frank, Rachel, Cohen Children's Medical Center, New York, New York, United States
- Vento, Suzanne, Cohen Children's Medical Center, New York, New York, United States
- Sethna, Christine B., Cohen Children's Medical Center, New York, New York, United States
- Shen, Carol L., Cohen Children's Medical Center, New York, New York, United States
Background
Kidney disease mortality is higher among Asian Americans (AAs) than non-Hispanic Whites (NHW). End-stage kidney disease (ESKD) prevalence is 1.6 times greater in AAs. Disaggregated data show Asian, Indian and Filipino groups face higher kidney-related mortality. Despite this, research on glomerular disease burden and ESKD progression in AAs remains limited.
Methods
Participants enrolled in either the NEPTUNE (n=393) or CureGN (n=2415) cohorts with self-reported race and ethnicity data were analyzed. AA (n=216) and NHW participants (n=1581) were compared. Primary outcomes were a composite of ESKD or 40% eGFR decline and complete remission. Secondary outcomes were the effects of age and racial subgroup. Linear, logistic regression, and Cox models (adjusted for age, sex, insurance, diagnosis, hypertension, and obesity) were utilized as appropriate to determine the association of AA and outcomes.
Results
Of the 216 AAs studied, 43% were females with a median age of 31 years [15.5-46.5]. 40% had IgA nephropathy, 26% minimal change disease, 19% membranous nephropathy, 15% focal segmental glomerulosclerosis. In CureGN, 5 Asians and 63 NHW people were multidrug resistant (p=0.187). Of the 185 AAs with racial subgroup in CureGN, 45 were Chinese, 47 South Asian, 4 Japanese, 19 Filipino, 10 Korean, and 16 Southeast Asian. There were no significant differences in baseline prevalent ESKD, UPCR, or eGFR between AAs and NHWs. While there was no significant difference in time to ESKD/40% eGFR decline, AAs had 37% reduced likelihood of complete remission (aHR 0.630 [0.495–0.801]) Stratified log-rank test by age showed significantly lower likelihood of remission in AA adults compared to NHW adults (>18 years) but no difference in AA children vs NHW children (<18 years).
Conclusion
This study highlights differences in AA treatment response and disease course that are not fully explained by baseline clinical factors. More research is needed to investigate the underlying biological, therapeutic, and social determinants contributing to these differences.